Hestia provides a novel approach to profoundly impact the 70% of cancer patients that are not benefiting from current standard of care. Hestia's tri-functional assets enable immune killer cells to penetrate and infiltrate the tumor microenvironment via unique anchor, activator and engager capabilities.